Artificial Intelligence (AI) in Cancer

Report Highlights

The global market for artificial intelligence (AI) in cancer is estimated to increase from $2.2 billion in 2024 to reach $6.3 billion by 2029, at a compound annual growth rate (CAGR) of 23.1% from 2024 through 2029.

Report Includes

• 42 data tables and 44 additional tables
• An up-to-date overview of the global markets for artificial intelligence (AI) in cancer
• Analysis of the global market trends, with data from 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
• Evaluation of the size of the market for artificial intelligence (AI) in cancer and revenue growth prospects, accompanied by a market share analysis by type, application, end user and region
• Assessment of market dynamics such as drivers, restraints and opportunities
• Coverage of current and emerging applications of AI in cancer and information on theranostics and generative AI tools
• A discussion on ESG challenges and practices in the industry
• Assessment of the vendor landscape, including the market shares of key companies, their product portfolios and financial overviews
• Information on recent mergers, acquisitions, expansions, collaborations, investments, divestments, product launches, and other strategic developments
• Company profiles of major players within the industry, including Siemens Healthineers, GE Healthcare, NVIDIA Corp., and Lunit Inc.

Report Scope

The report highlights AI technology's current and future market potential for cancer applications. It provides a detailed analysis of the market drivers, restraints and opportunities. The report also covers market projections through 2029 and presents a competitive environment and product analysis. The report provides market estimates and forecasts based on application, cancer type and region. By application type, the market is segmented into cancer screening, diagnosis, therapy, drug discovery and development and others. By cancer type, the market is segmented into breast, lung, prostate, gastrointestinal, brain and others. By end user, the market is segmented into hospitals, diagnostic centers, pharmaceutical companies and research institutions. The report includes profiles of the key companies with detailed information about their business segments, financials, product portfolios and recent developments.

By geographical region, the market is segregated into North America, Europe, Asia Pacific and the Rest of the world. The North American region includes countries the U.S., Canada and Mexico. Europe includes Germany, the U.K., Italy, France, Spain and the Rest of Europe; Asia-Pacific includes China, Japan, India, South Korea, Australia and the Rest of Asia-Pacific. For market estimates, data is provided for 2021 and 2022 as the historic years, 2023 as the base year and 2029 as the forecast year.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.